IN RE: EVENFLO COMPANY, INC., MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION,
No. 22-1133
United States Court of Appeals For the First Circuit
November 23, 2022
Lynch and Selya, Circuit Judges, and McElroy, District Judge.
APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS [Hon. Denise J. Casper, U.S. District Judge]
MIKE XAVIER; LINDSEY BROWN; MARCELLA REYNOLDS; MONA-ALICIA SANCHEZ; KEITH EPPERSON; CASEY HASH; JESSICA GREENSCHNER; LAUREN MAHLER; EDITH BRODEUR; DAVID A. SCHNITZER; ASHLEY MILLER; DANIELLE SARRATORI; HAILEY LECHNER; DESINAE WILLIAMS; ELISE HOWLAND; THERESA HOLLIDAY; JOSEPH WILDER; AMY SAPEIKA; NAJAH ROSE; SUDHAKAR RAMASAMY; TARNISHA ALSTON; EMILY NAUGHTON; TALISE ALEXIE; HEATHER HAMPTON; LINDSEY REED; KAREN SANCHEZ; BECKY BROWN; DEBORA DE SOUZA CORREA TALUTTO; KARYN ALY; JANETTE SMARR; KARI FORHAN; JOSHUA KUKOWSKI; ANNA GATHINGS; KRISTIN ATWELL; PENNY BIEGELEISEN; CARLA MATTHEWS; JILLI HIRIAMS; NATALIE DAVIS; CATHY MALONE; JEFFREY LINDSEY; LINDA MITCHELL; RACHEL HUBER; CASSANDRA HONAKER,
Plaintiffs, Appellants,
JANELLE WOODSON; DANA BERKLEY; JESSICA BLOSWICK; COLLEEN CODERRE; GRETA ANDERSON; KRISTEN BRINKERHOFF; LINDA FEINFELD; ANDREW GLADSTONE; GEORGETTE GLADSTONE; ELIZABETH GRANILLO; JANET JUANICH; TERESA MUGA; ASHLEY PERRY; ANGELICA RUBY,
Plaintiffs,
v.
EVENFLO COMPANY, INC.,
Defendant, Appellee,
GOODBABY INTERNATIONAL HOLDINGS LIMITED,
Defendant.
Jonathan D. Selbin, with whom Lieff Cabraser Heimann & Bernstein LLP, Steve W. Berman, Hagens Berman Sobol Shapiro LLP, Martha A. Geer, and Milberg Coleman Bryson Phillips Grossman, PLLC were on brief, for appellants.
Barbara A. Smith, with whom Dan H. Ball, Timothy J. Hasken, K. Lee Marshall, and Bryan Cave Leighton Paisner LLP were on brief, for appellee.
Philip S. Goldberg, Mark A. Behrens, Andrew J. Trask, and Shook Hardy & Bacon L.L.P. on brief for Juvenile Products Manufacturers Association, Chamber of Commerce of the United States of America, National Association of Manufacturers, and National Retail Federation, amici curiae.
* Of the District of Rhode Island, sitting by designation.
We hold that the plaintiffs’ pleadings plausibly demonstrate their standing to seek monetary relief. We also hold that the plaintiffs lack standing to seek declaratory and injunctive relief. We affirm in part, reverse in part, and remand for further proceedings.
I.
A.
We describe the facts as they appear in the plaintiffs’ complaint. Hochendoner v. Genzyme Corp., 823 F.3d 724, 728 (1st Cir. 2016).
The complaint asserts fifty-eight state law counts, including claims for fraudulent concealment, unjust enrichment, negligent misrepresentation, violations of various state consumer protection statutes, and breaches of implied warranties of merchantability under several other state statutes. The plaintiffs seek to certify a nationwide class of “[a]ll persons in the United States . . . who purchased an Evenflo ‘Big Kid’ booster seat between 2008 and the [complaint‘s filing],” as well as subclasses for each state, the District of Columbia, and Puerto Rico, and request monetary, injunctive, and declaratory relief.
The complaint alleges that “the market for children‘s car safety seats is generally grouped around . . . three basic designs that track, sequentially, with children‘s growing weights and heights: rear-facing seats, forward-facing seats with harnesses, and belt-positioning booster seats.” Evenflo manufactures and sells all three types of seats. The plaintiffs’ allegations concern the Big Kid booster seat, a model introduced in the early 2000s and said to offer similar features to a booster seat sold by one of Evenflo‘s leading competitors but intended to sell for approximately $10 less.
The complaint focuses on two misrepresentations Evenflo allegedly made about the Big Kid on its website and packaging, in marketing materials, and in its product descriptions at major retailers between 2008 and 2020.
First, Evenflo represented the Big Kid as safe for children as small as thirty pounds. The complaint alleges that Evenflo was aware “[a]s early as 1992 . . . that booster seats were not safe for children under 40 pounds,” based on a National Highway Traffic Safety Administration (“NHTSA“) “flyer that was [then] pending approval.” That flyer stated that a “toddler over one year of age, weighing 20 to 40 pounds, is not big enough for a booster.” Further, “since the early 2000s, the [American Academy of Pediatrics (“AAP“)] has advised that children who weigh 40 pounds or less . . . are best protected in a
Second, the complaint alleges that Evenflo misrepresented that the Big Kid had been “side impact tested.” Evenflo also stitched a “side impact tested” label onto the seats. Evenflo described its side impact testing on its website as meeting or exceeding federal standards and “simulat[ing] the government side impact tests conducted for automobiles.”
The plaintiffs describe this side impact testing claim as “misleading at best.” Between 2008 and 2020, NHTSA did not require or set a standard for side impact testing of booster seats. See
B.
The plaintiff Evenflo customers brought a number of suits against the company related to the Big Kid‘s marketing and safety in various federal district courts in early 2020. The Judicial Panel on Multidistrict Litigation centralized the actions and then transferred them to the District of Massachusetts in June 2020.
On October 20, 2020, the plaintiffs filed a consolidated amended class action complaint. This operative complaint names forty-three plaintiffs from twenty-eight states who purchased Big Kids for their children between 2010 and 2020. The complaint alleges that Evenflo‘s representations that the Big Kid was side impact tested and safe for children as small as thirty pounds were false or misleading. Three of the plaintiffs allegedly were involved in car accidents after purchasing the Big Kid, but none seek recovery for any physical injuries, if there were any, to their children. Although the exact language varies over the course of the complaint, the complaint typically alleges that “[h]ad [the plaintiffs] known about the defective nature of Evenflo‘s Big Kid booster seat[], [they] would not have purchased the seat, would have
On November 20, 2020, Evenflo moved to dismiss the complaint with prejudice. Evenflo argued that the plaintiffs lacked standing because they had not been injured by Evenflo‘s conduct, that the complaint failed to state a claim under
The district court concluded that the plaintiffs lacked standing and granted Evenflo‘s motion on January 27, 2022. See In re Evenflo, 2022 WL 252331, at *1, *5-6. The court reasoned that the plaintiffs had failed to establish any economic injury sufficient to pursue monetary relief because (1) the complaint did not allege that the seats failed to perform -- such that the plaintiffs had necessarily received the benefit of the bargain in purchasing them -- and (2) the plaintiffs had not plausibly shown that the seats were worth less than what they had paid for them or estimated their true value. See id. at *3-5. The court also concluded that the complaint did not allege any likelihood of future injury sufficient to create standing to pursue injunctive relief. See id. at *5-6. The court did not address Evenflo‘s other arguments for dismissal, and it did not specify whether the dismissal was to operate with or without prejudice. See id. at *1, *6.
The plaintiffs timely appealed.
II.
Article III of the Constitution limits “[t]he judicial Power” to “Cases” and “Controversies.”
“To satisfy th[e] standing requirement, a plaintiff must sufficiently plead three elements: injury in fact, traceability, and redressability.” Id.; see, e.g., TransUnion LLC v. Ramirez, 141 S. Ct. 2190, 2203 (2021). “An ‘injury in fact’ is ‘an invasion of a legally protected interest which is (a) concrete and particularized, and (b) “actual or imminent, not conjectural or hypothetical.“‘” Kerin, 770 F.3d at 981 (quoting Lujan v. Defs. of Wildlife, 504 U.S. 555, 560 (1992) (citations omitted)); see, e.g., TransUnion, 141 S. Ct. at 2203. Traceability “requires the plaintiff to show a sufficiently direct causal connection between the challenged action and the identified harm.” Katz, 672 F.3d at 71; see, e.g., Lujan, 504 U.S. at 560. And redressability requires the plaintiff to “show that a favorable resolution of her claim would likely redress the professed injury.” Katz, 672 F.3d at 72; see, e.g., Lujan, 504 U.S. at 561, 568-71.
Importantly, “plaintiffs must demonstrate standing for each claim that they press and for each form of relief that they seek (for example, injunctive relief and damages).” TransUnion, 141 S. Ct. at 2208.
We stress that the standing inquiry is distinct from the determination of
III.
We first consider the plaintiffs’ standing to pursue monetary relief. The complaint alleges only economic injury in the form of overpayment. In addition to statutory and common law claims explicitly based on misrepresentations, the complaint includes several claims pursuant to state statutes creating implied warranties of merchantability. These statutes are modeled on Uniform Commercial Code (“UCC“) section 2-314, which provides, inter alia, that “[g]oods to be merchantable must . . . conform to the promise or affirmations of fact made on the container or label if any.”
Evenflo attacks both the cognizability of overpayment as an injury in the absence of physical or emotional harm and the plausibility of the plaintiffs’ pleading of that injury in this case. We consider both arguments in turn.
A.
We first address Evenflo‘s more sweeping argument: that “where a plaintiff is not actually injured by an allegedly unsafe product, she does not have standing to pursue a claim for damages.” We disagree. This court has repeatedly recognized overpayment as a cognizable form of Article III injury. See Gustavsen v. Alcon Lab‘ys, Inc., 903 F.3d 1, 7-9 (1st Cir. 2018); In re Asacol Antitrust Litig., 907 F.3d 42, 47 (1st Cir. 2018) (recognizing “injury in the form of lost money fairly traceable to an allegedly unlawful supra-competitive price“); In re Pharm. Indus. Average Wholesale Price Litig., 582 F.3d 156, 190 (1st Cir. 2009) (recognizing “overpayment [as] a cognizable form of injury“).
Gustavsen illustrates that overpayment for a product -- even one that performs adequately and does not cause any physical or emotional injury -- may be a sufficient injury to support standing. There, this court concluded that a group of consumers had plausibly pleaded a concrete injury by alleging that they had overpaid for eyedrops as a result of bottles that dispensed larger than necessary drops. 903 F.3d at 7-9. The consumers did not claim, for standing purposes, that the eyedrops failed to perform or caused them any physical or emotional harm; they relied entirely on the allegation that, were the bottle more efficiently designed, they would have spent less money on the product. See id.
Evenflo seeks to distinguish Gustavsen by characterizing it as involving “the loss of a product that a company forced [the plaintiffs] to waste.” But Gustavsen did not turn on the fact that the plaintiffs were wasting portions of a consumable product;
Kerin also does not undercut the plaintiffs’ standing here. The plaintiff there did advance an argument that he had been injured by overpaying for a product, but did not argue that the source of the injury was a misrepresentation. See 770 F.3d at 983-84, 984 n.3. The plaintiff‘s purported injury instead rested entirely on allegations that the product -- which had been approved as to safety against the alleged risk by state regulators -- was defective, or at least unsafe, as a result of vulnerability to lightning strikes, without any argument that the product‘s manufacturer had misrepresented its quality. See id. at 983-84. This court held that, because the purported harm rested entirely on a purported risk of future injury ruled out by regulatory authorities, the plaintiff‘s failure to allege “facts sufficient to assess the likelihood of future injury” or establish that the product would be the cause of any damage rendered “the alleged risk of harm . . . too speculative to give rise to a case or controversy.” Id. at 985; see id. at 983-85; see also Clapper v. Amnesty Int‘l USA, 568 U.S. 398, 409 (2013) (explaining that plaintiffs asserting injury based on risk of future harm bear burden of showing “injury is not too speculative for Article III purposes” (quoting Lujan, 504 U.S. at 565 n.2)). In contrast, the plaintiffs here do not rely on a risk of future injury as grounds for economic loss; instead, they argue that they overpaid (or purchased the product at all) because of Evenflo‘s past misrepresentations.
Our conclusion that the plaintiffs have standing as to these claims is consistent with precedent from other circuits addressing similar allegations.
Multiple Second Circuit decisions have determined that plaintiffs had standing based on overpayment due to a defendant‘s false or misleading statements. See Langan v. Johnson & Johnson Consumer Cos., 897 F.3d 88, 92 (2d Cir. 2018) (finding standing where plaintiff alleged she paid more for product based on purported misrepresentation); John v. Whole Foods Mkt. Grp., Inc., 858 F.3d 732, 736 (2d Cir. 2017) (finding standing on an overpayment theory where the plaintiff purchased prepackaged groceries labeled and priced as being heavier than they really were); Axon v. Fla.‘s Nat. Growers, Inc., 813 F. App‘x 701, 703-04 (2d Cir. 2020) (finding standing where the plaintiff “suffered an injury-in-fact because she purchased products bearing allegedly misleading labels and sustained financial injury -- paying a premium -- as a result“).
Although the Third Circuit has, in several decisions cited by Evenflo, rejected plaintiffs’ efforts to invoke overpayment injuries in cases involving allegedly misleading marketing where the plaintiffs did not suffer any physical injury, its decisions have emphasized the plaintiffs’ failure to plausibly plead such an injury. See, e.g., In re Johnson & Johnson Talcum Powder Prods. Mktg., Sales Pracs. & Liab. Litig., 903 F.3d 278, 282-83, 285-90 (3d Cir. 2018). We conclude that the plaintiffs in this case have adequately pleaded the injury.
The Fifth Circuit, in Cole v. General Motors Corp., 484 F.3d 717 (5th Cir. 2007), held that purchasers of vehicles with allegedly defective airbag systems that could inadvertently deploy had standing
The Sixth Circuit, too, recognizes that a “[p]laintiff[‘s] allegation that [she] suffered a monetary loss by paying more for [a product] because of the [defendant‘s] misrepresentation establishes a cognizable injury.” Loreto v. Procter & Gamble Co., 515 F. App‘x 576, 581 (6th Cir. 2013).
The Seventh Circuit has also concluded that an overpayment injury is cognizable for standing purposes. See In re Aqua Dots Prods. Liab. Litig., 654 F.3d 748, 750-51 (7th Cir. 2011). Aqua Dots held that a group of parents who had bought, but whose children had not been injured by, a defective toy had standing to sue based on a “financial [injury]: they paid more for the toys than they would have, had they known of the risks the [toys] posed to children.” Id. at 751. While the plaintiffs in this case pursue misrepresentation claims, rather than the products liability claims raised in Aqua Dots, see id. at 750-51, the injury is analogous, as the complaint here alleges that the plaintiffs paid more than they would have if Evenflo had not misrepresented its products.
Eighth Circuit precedent less clearly favors the plaintiffs but is ultimately consistent with their theory of standing. That circuit has held that “plaintiffs claiming economic injury do not have Article III standing in product defect cases unless they show a manifest defect.” Johannessohn v. Polaris Indus. Inc., 9 F.4th 981, 988 (8th Cir. 2021) (finding no standing where plaintiffs sought to rely on overpayment theory of injury but did not plead that every product demonstrated the alleged defect). The plaintiffs’ case sounds in misrepresentation rather than products liability, however. And the Eighth Circuit has also held that, even if the defect must manifest to support standing, it need not necessarily cause any physical injury; for this reason, consumers who had purchased pipes susceptible to cracking could claim standing based on that defect when the pipes cracked but did not actually leak. In re Zurn Pex Plumbing Prods. Liab. Litig., 644 F.3d 604, 608-09, 616-17 (8th Cir. 2011). While the plaintiffs here do not assert that every Big Kid they purchased exhibited a defect, the complaint does allege that Evenflo‘s misrepresentations applied to and influenced each purchase.2
A line of Ninth Circuit decisions holds that “[i]n a false advertising case, plaintiffs [have standing] if they show that, by relying on a misrepresentation on a product label, they ‘paid more for a product than they otherwise would have paid, or bought it when they otherwise would not have done so.‘” Reid v. Johnson & Johnson, 780 F.3d 952, 958 (9th Cir. 2015) (quoting Hinojos v. Kohl‘s Corp., 718 F.3d 1098, 1104 n.3 (9th Cir. 2013)); accord, e.g., Mazza v. Am. Honda Motor Co., 666 F.3d 581, 595 (9th Cir. 2012), overruled on other grounds by Olean Wholesale Grocery Coop., Inc. v. Bumble Bee Foods LLC, 31 F.4th 651 (9th Cir. 2022).3
Finally, the Eleventh Circuit has held that a “person experiences an economic injury” that “qualifies as a concrete injury” for standing purposes “when, as a result of a deceptive act or an unfair practice, he is deprived of the benefit of his bargain.” Debernardis v. IQ Formulations, LLC, 942 F.3d 1076, 1084 (11th Cir. 2019). The Debernardis plaintiffs sought damages related to their purchase of allegedly adulterated dietary supplements; they did not allege that “the supplements failed to perform as advertised” or inflicted physical harm, but instead asserted that “[b]ecause the supplements had no economic value, each plaintiff paid an ‘unwarranted amount’ to purchase the supplements.” Id. at 1082, 1085-86. Evenflo seeks to distinguish Debernardis on the grounds that the supplement purchasers alleged that the adulterated products were worthless, see id. at 1084-86, but this distinction makes no difference in the standing inquiry. While the Eleventh Circuit did discuss the supplements’ alleged worthlessness, it did not state, or even imply, that a diminution -- rather than a complete loss -- in value would not constitute a concrete injury. See id. On the contrary, it observed that when a “product retains some value,” a plaintiff‘s “damages are less than the entire purchase price” -- but that plaintiff is nonetheless injured. Id. at 1084. And, in any event, a requirement that plaintiffs allege that a product is worthless in order to invoke an overpayment injury is irreconcilable with the rule that “a relatively small economic loss -- even an ‘identifiable trifle’ -- is enough to confer standing.” Katz, 672 F.3d at 76 (quoting Adams v. Watson, 10 F.3d 915, 924 (1st Cir. 1993)).
Evenflo, supported by its amici, argues that this body of precedent recognizing overpayment injuries is in tension with the Supreme Court‘s recent decisions in Spokeo v. Robins, 578 U.S. 330 (2016), and TransUnion. Those decisions examined the concreteness requirement for injury in fact,
B.
We turn to Evenflo‘s argument that the complaint does not allege sufficient facts to plausibly demonstrate that, as a result of Evenflo‘s misrepresentations, the plaintiffs spent more money than they otherwise would have. See Hochendoner, 823 F.3d at 731. In conducting this “context-specific” plausibility inquiry, we “‘[must] draw on [our] judicial experience and common sense’ . . . [and] read [the complaint] as a whole.” García-Catalán v. United States, 734 F.3d 100, 103 (1st Cir. 2013) (first alteration in original) (quoting Ashcroft v. Iqbal, 556 U.S. 662, 679 (2009)). We conclude that, read as a whole, the complaint‘s allegations satisfy the plausibility standard.
The complaint typically alleges that “[h]ad [the plaintiffs] known about the defective nature of Evenflo‘s Big Kid booster seat[], [they] would not have purchased the seat, would have paid less for it, or instead would have purchased one of many safer available alternatives.”4 The references to “know[ing] about the defective nature” of the Big Kid are fairly read in the context of the complaint to refer to how the plaintiffs would have acted were it not for Evenflo‘s misrepresentations, and Evenflo does not argue otherwise. Instead, it contends that these allegations fall short of plausibly demonstrating any financial injury.
Evenflo raises doubts about the plausibility of the purported injury under each of the plaintiffs’ proposed alternative courses of action. First, it argues that the plaintiffs could not plausibly “forgo buying [any] car seat, given that the use of a car seat is required by law in each state where the [p]laintiffs reside.” But the complaint alleges
Next, Evenflo attacks the plaintiffs’ claim that they might have paid less for the Big Kid for offering no “measure” or “basis” for the decreased price. But it is a reasonable inference that, if Evenflo had not marketed the Big Kid as safe for children as small as thirty pounds and as side impact tested, the product would have commanded a lower price, allowing the plaintiffs to pay less for it.5 At this stage of the litigation, that inference suffices to support the plaintiffs’ standing even without quantification of the change in market value.
Finally, Evenflo highlights the plaintiffs’ allegation that, were it not for Evenflo‘s misrepresentations, they may have purchased a safer alternative seat. It points out that the complaint does not allege that such alternatives would have been cheaper -- and in fact alleges that the Big Kid was roughly $10 cheaper than its chief competitor. This argument has some force, but we conclude that, at the pleading stage, it does not defeat the plaintiffs’ standing. Cf. Axon, 813 F. App‘x at 704 (recognizing injury even where the plaintiff “fail[ed] to identify the prices of competing products to establish the premium that she paid“). Given that purchasing a different seat is only one of the three alternative courses of action described in the complaint and the possibility that a cheaper alternative exists, the complaint, taken as a whole, plausibly supports the plaintiffs’ argument that Evenflo‘s misrepresentations caused them to overpay.
Evenflo also faults the plaintiffs for “offer[ing] no theories of how damages could be measured“; although it concedes that “[a] precise amount of damages need not be pleaded,” it asserts that the plaintiffs must at least offer “the formula” for measuring damages. But at the pleading stage, to demonstrate Article III standing, plaintiffs need not quantify or offer a formula for quantifying their injury. See, e.g., TransUnion, 141 S. Ct. at 2211 (recognizing possibility of “an actual harm that . . . is not readily quantifiable“); García-Catalán, 734 F.3d at 103 (emphasizing that the plausibility standard “does not demand ‘a high degree of factual specificity‘” in the context of a motion to dismiss under Rule 12(b)(6) (quoting Grajales v. P.R. Ports Auth., 682 F.3d 40, 47 (1st Cir. 2012))).
We note that the plaintiffs’ allegations readily satisfy the remaining requirements of traceability and redressability. Indeed, Evenflo makes no argument to the contrary. The complaint alleges that the plaintiffs overpaid because of Evenflo‘s misrepresentations, making their injury traceable to the challenged conduct. See, e.g., Katz, 672 F.3d at 76-77. And monetary relief would compensate them for their injury, rendering the injury redressable. See, e.g., Gustavsen, 903 F.3d at 9.
As to arguments going to whether a claim is stated -- for instance, Evenflo‘s assertions that its statements were not false, misleading, or inconsistent with regulatory requirements -- they are not properly before us on appeal. See Hochendoner, 823 F.3d at 734 (distinguishing between inquiries under Rules 12(b)(1) and 12(b)(6)).
As the case proceeds, the plaintiffs will bear the burden of substantiating their alleged injuries, and Evenflo may challenge their success in doing so. See, e.g., Valentin v. Hosp. Bella Vista, 254 F.3d 358, 362-64 (1st Cir. 2001) (discussing different forms of jurisdictional challenges). Evenflo raised a variety of other arguments for dismissal before the district court which that court did not reach. We leave it for the district court to consider those arguments in the first instance. See, e.g., Hochendoner, 823 F.3d at 735 (remanding case for district court to consider alternative bases for dismissal).
IV.
The plaintiffs’ briefs do not address their standing to pursue declaratory relief, and so they have waived any argument on that point. See, e.g., FinSight I LP v. Seaver, 50 F.4th 226, 236 (1st Cir. 2022) (argument “presented in conclusory fashion” is waived).
“Standing for injunctive relief depends on ‘whether [the plaintiff is] likely to suffer future injury . . . .‘” Laufer v. Acheson Hotels, LLC, 50 F.4th 259, 276 (1st Cir. 2022) (quoting City of Los Angeles v. Lyons, 461 U.S. 95, 105 (1983)). Nothing in the plaintiffs’ complaint suggests any possibility of future harm; for example, the complaint does not allege that any plaintiff intends to purchase a Big Kid in the future. The plaintiffs’ assertions about their past behavior do not plausibly allege any likelihood of relying on Evenflo‘s advertising or purchasing Big Kids in the future, and so there is no impending future injury that an injunction might redress. The plaintiffs argue that this reasoning would allow Evenflo to “continue falsely marketing its Big Kid seats to parents and grandparents . . . who will continue to purchase them because of Evenflo‘s false statements.” But a hypothetical future injury to other unnamed “parents and grandparents” does not give these plaintiffs standing.
V.
Finally, the plaintiffs request that we “amend, or direct the district court to amend, the judgment to provide for dismissal without prejudice.”6 Although Evenflo‘s motion to dismiss requested that the district court “dismiss[] the [complaint] . . . with prejudice,” the district court‘s
The plaintiffs correctly point out that “a dismissal for lack of Article III standing must operate without prejudice.” Hochendoner, 823 F.3d at 736 (emphasis added). Given the ambiguity in the district court‘s order, we “direct the district court, on remand, to clarify its judgment to reflect that the judgment is to operate without prejudice” to the extent we affirm the dismissal for lack of standing.7 Id.
VI.
We affirm in part, reverse in part, and remand the matter for further proceedings consistent with this opinion. All parties shall bear their own costs on appeal.
